Drug intelligence / Profile preview

MT3

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Injection

Overview

MT3 is a monoclonal antibody developed to investigate the role of the CD45RB ectodomain region in immunocyte-thyrocyte signaling, particularly in autoimmune thyroid diseases like Hashimoto's thyroiditis and Graves' disease. In vitro studies showed that MT3 stimulated peripheral blood mononuclear cell proliferation. In severe combined immunodeficient (SCID) mice engrafted with human thyroid cells, MT3 maintained or up-regulated the expression of human leukocyte antigen (HLA)-DR and intercellular adhesion molecule (ICAM)-1 on thyrocytes.

Targets

CD45RB

Beyond the preview

Go deeper on MT3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT3.

Explore the full profile